Author:
Zhao Yuanyuan,Ma Yuxiang,Fan Yun,Zhou Jianya,Yang Nong,Yu Qitao,Zhuang Wu,Song Weifeng,Wang Zhongmin Maxwell,Li Baiyong,Xia Yu,Zhao Hongyun,Zhang Li
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference31 articles.
1. Cancer treatment and survivorship statistics, 2022;Miller;CA A Cancer J. Clin.,2022
2. Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China;Gou;Lung Cancer (Auckl),2014
3. NCCN clinical practice guidelines in oncology: non-small cell lung cancer, Version 1.2023;Ettinger;J. Nat. Comprehen. Cancer Network: JNCCN,2022
4. Randomized phase III trial of docetaxel vs vinorelbine or ifosfamide in patients with advancednon-small-cell lung cancer previously treated with platinum-containingchemotherapy;Fossella;J. Clin. Oncol.,2000
5. Docetaxel (Taxotere)shows survival and quality-of-life benefits in the second-line treatment of non-small-celllung cancer: a review of two phase III trials;Shepherd;Semin. Oncol.,2001
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献